| 2025-12-01 |
详情>>
内部人交易：
Puri Raj K.等共交易14笔
|
| 2025-11-06 |
详情>>
股本变动：
变动后总股本39696.80万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.94美元,归母净利润-3.19亿美元,同比去年增长-8.67%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.69美元,归母净利润-2.28亿美元,同比去年增长-8.45%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.36美元,归母净利润-1.16亿美元,同比去年增长-2.82%
|
| 2025-04-28 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect seven directors named in the proxy statement accompanying this notice to serve until the 2026 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2025;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 12,500,000 shares;
5.To approve an amendment to our 2020 Employee Stock Purchase Plan (the “2020 ESPP”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder by 1,000,000 shares.
|
| 2025-02-27 |
详情>>
业绩披露：
2024年年报每股收益-1.28美元,归母净利润-3.72亿美元,同比去年增长16.18%
|
| 2025-02-27 |
详情>>
业绩披露：
2022年年报每股收益-2.49美元,归母净利润-3.96亿美元,同比去年增长-15.67%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.03美元,归母净利润-2.94亿美元,同比去年增长10.39%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.76美元,归母净利润-2.1亿美元,同比去年增长1.79%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.42美元,归母净利润-1.13亿美元,同比去年增长-5.22%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect seven directors named in the proxy statement accompanying this notice to serve until the 2025 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 29,700,000 shares to 36,700,000 shares and permit share recapture from our 2014 Equity Incentive Plan;
5.To approve an amendment to our 2020 Employee Stock Purchase Plan (the “2020 ESPP”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 1,400,000 shares to 1,900,000 shares.
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-1.89美元,归母净利润-4.44亿美元,同比去年增长-12.16%
|
| 2024-02-17 |
复牌提示：
2024-02-16 14:56:26 停牌，复牌日期 2024-02-16 15:40:00
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.44美元,归母净利润-3.28亿美元,同比去年增长-12.76%
|
| 2023-04-26 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect seven directors named in the proxy statement accompanying this notice to serve until the 2024 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2023;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 20,700,000 shares to 29,700,000 shares;
5.To approve an amendment to our 2020 Iovance Employee Stock Purchase Plan (the “2020 ESPP”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 500,000 shares to 1,400,000 shares;
6.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 300,000,000 shares to 500,000,000 shares.
|
| 2022-04-27 |
股东大会：
将于2022-06-10召开股东大会
会议内容 ▼▲
- 1.To elect six directors named in the proxy statement accompanying this notice to serve until the 2023 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of the Company’s common stock authorized for issuance thereunder from 14,000,000 shares to 20,700,000 shares.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-27 |
股东大会：
将于2021-06-11召开股东大会
会议内容 ▼▲
- 1.To elect seven directors named in the proxy statement accompanying this notice to serve until the 2022 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021.
|
| 2020-04-27 |
股东大会：
将于2020-06-08召开股东大会
会议内容 ▼▲
- 1.To elect seven directors named in the proxy statement accompanying this notice to serve until the 2021 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers;
4.To approve an amendment to our 2018 Equity Incentive Plan (the “2018 Plan”) to increase the number of shares of common stock authorized for issuance thereunder from 6,000,000 shares to 14,000,000 shares;
5.To approve our 2020 Employee Stock Purchase Plan (“2020 ESPP”);
6.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020.
|
| 2019-04-29 |
股东大会：
将于2019-06-10召开股东大会
会议内容 ▼▲
- 1.To elect six directors named in the proxy statement accompanying this notice to serve until the 2020 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 150,000,000 shares to 300,000,000 shares;
4.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2019.
|
| 2018-04-25 |
股东大会：
将于2018-06-06召开股东大会
会议内容 ▼▲
- 1.To elect six directors named in the proxy statement accompanying this notice to serve until the 2019 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To approve the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan;
4.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2017-04-20 |
股东大会：
将于2017-06-01召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to serve until the 2018 Annual Meeting of Stockholders;
2.To approve, by non-binding advisory vote, the compensation of our named executive officers;
3.To approve the reincorporation of Lion Biotechnologies, Inc. from the State of Nevada to the State of Delaware, pursuant to a plan of conversion;
4.To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2017;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2016-07-07 |
股东大会：
将于2016-08-16召开股东大会
会议内容 ▼▲
- 1. To elect seven directors to serve until the 2017 Annual Meeting of Stockholders;
2. To approve, by non-binding advisory vote, the compensation of our named executive officers;
3. To approve an amendment to the 2014 Equity Incentive Plan, as amended (as so amended, the “2014 Plan”), to increase the number of shares of the Company’s authorized common stock for issuance under the 2014 Plan from 4,000,000 shares to 9,000,000 shares;
4. To approve the conversion provisions of our Series B Preferred Stock that permit the shares of our Series B Preferred Stock to become convertible into shares of our common stock and the issuance of the shares of common stock issuable upon the conversion of the Series B Preferred Stock;
5. To ratify the appointment of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2016;
6. To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|